Kyowa Hakko manufactures and markets pharmaceuticals, bio-products, liquor, food and chemicals. Kyowa aims to be the Japanese leader in biopharmaceuticals, particularly in the therapeutic areas of cancer and allergy. The principal pharmaceutical products are KW-2170 for malignant tumors, KW-6002 for Parkinson’s disease and KW-7158 for urinary incontinence. In 2001, the company had a R&D expenditure of ¥28,921 M.